CBR Systems, Inc.

Banking newborn stem cells an option for couples choosing gestational carrier TRUMBULL, Conn., July 27, 2023 /PRNewswire/ -- CooperSurgical, a global leader in fertility and women's health, announced that Chrissy Teigen, mom, New York Times best-selling cookbook author, television host and entrepreneur, selected Cord Blood Registry® (CBR®) to bank the umbilical cord blood and cord tissue of her newborn, Wren Alexander Stephens, who was born via gestational carrier in June. "Expectant parents may be confused if they can preserve their newborn's stem cells when they are using a surrogate or gestational carrier. The process of collecting and storing cord blood and cord tissue is no different for parents who are growing their families through use of a gestational carrier versus a pregnancy carried by the intended parent," stated board-certified OB/GYN and CBR spokesperson, Dr. Christine Sterling. "As Chrissy's example demonstrates, the option to bank cord blood and tissue is still very much available to parents who build their families in a wide variety of ways." CBR and Teigen launched an educational campaign earlier this year to raise awareness about the potential benefits of banking newborn stem cells from cord blood and cord tissue. CBR is the largest family newborn stem cell preservation company in the world, helping parents store newborn stem cells from cord blood and cord tissue for their children. CBR is the #1 choice for parents1 and the most recommended cord blood preservation company by OB/GYNs.2 "CBR is dedicated to educating families about the life-saving potential of newborn stem cells, helping to provide them with access to current treatments and future clinical therapies," stated Holly Sheffield, President, CooperSurgical. "We are delighted that our campaign is educating more families that newborn stem cell preservation is a viable option when using a gestational carrier, and we are proud to continue working with Chrissy over the next several months." For more information about CBR and the benefits of cord blood banking, please visit . About CBR by CooperSurgical Cord Blood Registry® (CBR®) is the largest family newborn stem cell preservation company in the world, helping parents store stem cells from cord blood and cord tissue for their children. Founded in 1994, CBR is the #1 choice for parents1 and most recommended by OB/GYNs for newborn stem cell preservation.2 The company has released over 700 samples intended for use in transplant medicine and regulated investigational regenerative medicine applications. CBR is here to help expand the possibilities of what newborn stem cell therapies can do for families and give parents the confidence to Bank on CBR™. More information can be found at . About CooperSurgical CooperSurgical® is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options. CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's health care clinicians. More information can be found at . About CooperCompanies CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit . Disclaimer: The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available. Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.'s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord–derived stem cells. Cbr Systems, Inc.'s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells. References: Internal source. Data on file. Blind survey, Egg Strategy, 10/19, funded by CBR. Contact: CooperSurgical EvolveMKD [email protected] SOURCE CooperSurgical®

The rise in awareness related to the benefits of using cord blood stem cells for the treatment of chronic diseases, such as cancer, has led to an increase in the government initiative leading to an increase in number of cord blood banks, which is expected to fuel the market growth of cord blood banking services. The global cord blood banking services market accounted for $1,126 million in 2016, and is estimated to reach at $2,772 million by 2023, registering a CAGR of 13.8% from 2017 to 2023. North America was the highest revenue contributor in the global market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period. Government authorities have supported research and clinical trials of cord blood stem cells, thus increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. In detail along with the table of contents, please click on the link below: The private cord blood banks are privately owned banks where the parents can store the cord blood of newborn for future use such as for treatment of certain chronic disease. In private banks, charges are incurred for the collection, processing, and storage of cord blood. Thus, the public cord blood banks possess competitive advantages in developed regions such as North America and Europe. Drivers, Restraints, and Opportunities The impact of the driving factors is expected to surpass the effect of restraints. Moreover, advancement in therapeutic application, untapped opportunities in the developing regions, and initiatives to spread awareness are expected to provide new avenues for the growth of market in the near future. High cost associated with the processing, difficulty in finding a match in the donor list of public cord blood banks, and legal & ethical issues related to collection of cord blood are expected to hamper this growth. Conversely, advancement in the stem cell therapeutics and presence of untapped potential in the developing and developed regions are expected to provide various opportunities to the cord blood banking services. Key Findings of the Cord Blood Banking Services Market: The private cord blood bank segment is anticipated to grow at the highest rate during the analysis period. Germany was the highest revenue-generating country in the European market in 2016, and is expected to continue its dominance during the forecast period. In 2016, North America dominated global cord blood banking services market, and is estimated to continue this trend in the near future. China is expected to grow at the highest rate in the Asia-Pacific region. Latin America was the largest contributor in the LAMEA region. Key market players- China Cord Blood Corporation Cord Blood America, Inc. CBR Systems, Inc. Cordlife Group Limited Cryo-Cell International, Inc. Cryo-Save AG Lifeforce Cryobanks National Cord Blood Program ViaCord, Inc. Virgin Health Bank CordVida Americord CryoHoldco Vita34. Allied Market Research Coverage on the Healthcare Domain: Liver Disease Treatment Market by Treatment Type (Anti-Rejection Drugs/Immunosupressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, IImmunoglobulins, Corticosteroids) - Global Opportunity Analysis and Industry Forecast, 2021 – 2028 Ostomy Drainage Bags Market by Types (Ileostomy Bags, Colostomy Bags, Urostomy Bags), Geography (North America, Europe, Asia Pacific, LAMEA) - Global Opportunity Analysis and Industry Forecast, 2021 – 2028 About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com

Albany, New York, April 09, 2019 (GLOBE NEWSWIRE) -- According to a recent report by Transparency Market Research, the global umbilical cord blood banking market, is likely to expand at a steady CAGR of 11.4% within the forecast period from 2017 to 2025. In 2016, the umbilical cord blood banking market was valued around worth US$3,124.4 mn. This figure is expected to reach around worth of US$8,178.1 mn by the end of 2025. Umbilical cord blood considered as a potential wellspring of various stem cells, especially in heterogeneous population all over the world, point to the tremendous ubiquity of their storage. The expanding use of umbilical cord blood in the treatment of lymphoma, leukemia, and sarcoma, and immunological issues is supporting the demand for their banking. The promising utilization of umbilical cord blood in cell treatment research is helping the market to grow quickly. Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19922 Promising Scope in Cell Research Treatment to Fuel Market Demand The market is tremendously profiting by the immense prospect of umbilical cord blood in studying new stem cell based medical procedures, both in hematological and non-hematological ailments, particularly in developed countries, for example, the U.S., the U.K., and Germany. Fast walk made in the field of cord blood stockpiling and preparing innovations looks good will make rewarding roads in the market. Governments and a public policies in different developed and developing economies are leaving upon activities to make awareness about the advantages of umbilical cord blood banking. Generous supports pouring in various developing nations are helping in the expansion of the market in the forthcoming years. Request PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19922 Lack of Standard Policies Regarding Umbilical Cord Banking to Hinder Growth Nevertheless, the absence of standard and clear policies for the people with respect to umbilical cord blood banking in various nations across the world may limit market players to understand its maximum capacity. Moreover, community oriented efforts to build up more clear universal rules for better utilization of umbilical cord blood in cell-based research will grow the capability of the market, along with more lucrative opportunities. Request For Discount On This Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=19922 On the basis of type of storage, the global umbilical cord blood banking market is segment into private cord blood banks and public cord blood banks. Among these, in 2016, private cord blood banks segment held around 65.0% of the umbilical cord blood banking market. Private cord blood banks provide cord blood storage regarding personal usage, for example people in the family or acquaintance. Based on geography, in 2016, the North America regional market for umbilical cord blood banking is dominated the global market, accounting for over 38.2% share in the entire market. The mentioned regional market is likely to sustain its lead and growth in the coming few years as well, mainly due to surging demand for umbilical cord blood in the research for stem cell. Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=19922 Market to Witness Fragmented Vendor’s Landscape The global umbilical cord blood banking market represents a highly fragmented competitive scenario marked by large number of companies. The collective share of three key companies in the market is just around 7% of umbilical cord blood banking market. In the past few years, the significant rise in private cord blood banking firms is estimated to surge the level of competition. However, the intense fragmentation in the market, in highly regulated by global and regional laws, both, with an intention to promote better medical usage of umbilical cord blood. The major players leading in the global umbilical cord blood banking market are LifeCell, StemCyte Inc., Vita 34 AG, Cryo-Save AG, Cordlife Group Ltd., Cryo-Cell International, Inc., China Cord Blood Corporation, ViaCord Inc., Cord Blood America, Inc., and CBR Systems, Inc. More Trending Reports by Transparency Market Research: Calcitriol Market - https://www.transparencymarketresearch.com/calcitriol-market.html Rivaroxaban Market - https://www.transparencymarketresearch.com/rivaroxaban-market.html Frankincense Extracts Market - https://www.transparencymarketresearch.com/frankincense-extracts-market.html Dementia Drugs Market - https://www.transparencymarketresearch.com/dementia-drugs-market.html About TMR Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. ContactMr. Rohit BhiseyTransparency Market ResearchState Tower90 State Street,Suite 700,Albany, NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: http://www.transparencymarketresearch.com Research Blog: http://theglobalhealthnews.com/